A forgotten option: megestrol acetate’s effectiveness and safety in HR+/HER2-negative metastatic breast cancer — insights from a contemporary patient cohort
BACKGROUND: The ABC 6/7 guidelines recommend megestrol acetate (MA) as a later-line hormonal option for HR+/HER2− metastatic breast cancer (MBC) when targeted therapies are unavailable, though current evidence on its efficacy and safety remains limited. MATERIALS AND METHODS: This retrospective stud...
I tiakina i:
| Ngā kaituhi matua: | , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Via Medica
2026-05-01
|
| Rangatū: | Reports of Practical Oncology and Radiotherapy |
| Ngā marau: | |
| Urunga tuihono: | https://journals.viamedica.pl/rpor/article/view/110809 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|